Intercept Wants More Time to Address EMA’s Questions Over Its NASH Treatment
EU Review Of Obeticholic Acid Began Around 18 Months Ago
The marketing application for obeticholic acid, Intercept’s potential new treatment for advanced fibrosis due to nonalcoholic steatohepatitis (NASH), was rejected in the US and now the company says it needs extra time to respond to questions about its EU filing.
